| Phase 19 trials |
|
Phase 1
|
NCT06211179 |
Jan → Jun 2024 |
— |
Bristol-Myers Squibb |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05719805 |
Feb → Jul 2023 |
— |
Bristol-Myers Squibb |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05658146 |
Jan → Jul 2023 |
— |
Bristol-Myers Squibb |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05362045 |
May → Aug 2022 |
— |
Bristol-Myers Squibb |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05320094 |
Apr → Sep 2022 |
— |
Bristol-Myers Squibb |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05135871 |
Oct 2021 → Feb 2022 |
hypertrophic cardiomyopathy |
LianBio LLC |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02480296 |
Aug 2015 → Jul 2016 |
— |
MyoKardia, Inc. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02356289 |
Jan → Jul 2015 |
— |
MyoKardia, Inc. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02329184 |
Dec 2014 → Mar 2016 |
hypertrophic cardiomyopathy |
MyoKardia, Inc. |
Completed
|
No outcome recorded
|
| Phase 24 trials |
|
Phase 2
|
NCT04766892 |
Mar 2021 → Feb 2024 |
diastolic heart failure |
Bristol-Myers Squibb |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03496168 |
Apr 2018 → Nov 2023 |
hypertrophic cardiomyopathy |
Bristol-Myers Squibb |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03442764 |
Mar 2018 → Jan 2020 |
hypertrophic cardiomyopathy |
MyoKardia, Inc. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT02842242 |
Aug 2016 → Nov 2017 |
hypertrophic cardiomyopathy |
MyoKardia, Inc. |
Completed
|
No outcome recorded
|
| Phase 2/31 trial |
|
Phase 2/3
|
NCT03723655 |
Sep 2018 → Jan 2026 |
hypertrophic cardiomyopathy |
Bristol-Myers Squibb |
Completed
|
No outcome recorded
|
| Phase 36 trials |
|
Phase 3
|
NCT06253221 |
Apr 2024 → Nov 2025 overdue |
— |
Bristol-Myers Squibb |
Active not recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT05582395 |
Dec 2022 → Mar 2025 |
— |
Bristol-Myers Squibb |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT05414175 |
Aug 2022 → Nov 2023 |
hypertrophic cardiomyopathy |
Bristol-Myers Squibb |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT05174416 |
Jan 2022 → Mar 2023 |
hypertrophic cardiomyopathy |
LianBio LLC |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT04349072 |
Jul 2020 → Feb 2022 |
hypertrophic cardiomyopathy |
Bristol-Myers Squibb |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT03470545 |
May 2018 → Mar 2020 |
hypertrophic cardiomyopathy |
MyoKardia, Inc. |
Completed
|
No outcome recorded
|
| Phase 43 trials |
|
Phase 4
|
NCT07103655 |
Jan → Jul 2026 overdue |
hypertrophic cardiomyopathy |
Second Affiliated Hospital, School of Medicine, Zhejiang University |
Not yet recruiting
|
No outcome recorded
|
|
Phase 4
|
NCT07004972 |
Sep 2025 → Dec 2027 expected |
hypertrophic cardiomyopathy |
Bristol-Myers Squibb |
Active not recruiting
|
No outcome recorded
|
|
Phase 4
|
NCT06112743 |
Jan 2024 → Jul 2026 overdue |
— |
Bristol-Myers Squibb |
Active not recruiting
|
No outcome recorded
|
| Phase not applicable3 trials |
| — |
NCT07120776 |
Mar 2026 → Oct 2028 expected |
hypertrophic cardiomyopathy, myocardial ischemia |
University of Manchester |
Recruiting
|
No outcome recorded
|
| — |
NCT06947590 |
Apr 2025 → Feb 2026 overdue |
hypertrophic cardiomyopathy |
Xu Liu |
Active not recruiting
|
No outcome recorded
|
| — |
NCT06856265 |
Feb → Dec 2025 overdue |
hypertrophic cardiomyopathy |
Shanghai Chest Hospital |
Not yet recruiting
|
No outcome recorded
|